Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians

(2017) S. Dirmesropian et al.   VACCINE

Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case–control study

(2016) Marcela Guevara et al.   Eurosurveillance

Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccine

(2016) Qi Liang et al.   Expert Review of Vaccines

Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States

(2016) Charles Stoecker et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Maternal Immunization with Pneumococcal Polysaccharide Vaccine: Persistence of Maternal Antibodies in Infants

(2016) Eitan N Berezin et al.   JOURNAL OF TROPICAL PEDIATRICS

Choice of optimal vaccination tactics against pneumococcal infection from immunological and clinical standpoints in patients with chronic obstructive pulmonary disease

(2016) A. D. Protasov et al.   TERAPEVTICHESKII ARKHIV

Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses

(2016) Kenji Kawakami et al.   VACCINE

Vaccination of special populations: Protecting the vulnerable

(2016) Mark Doherty et al.   VACCINE

The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium

(2016) Adriaan Blommaert et al.   VACCINE

Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects

(2016) Karen Ciprero et al.   Human Vaccines & Immunotherapeutics

Inflammatory Markers and Immune Response to Pneumococcal Vaccination in HIV-Positive and -Negative Adults

(2016) Anita S. Iyer et al.   PLoS One

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults

(2015) Jong Gyun Ahn et al.   VACCINE

Long-lasting hyporesponsivenss induced by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in asplenic patients with β-thalassemia major

(2015) I. Papadatou et al.   VACCINE

The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old—Taiwan's PPV vaccination program

(2015) Ying-Huang Tsai et al.   VACCINE

Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 2 to 70 year old healthy people in China: A phase III double blind, randomized clinical trial

(2015) Guifan Li et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial

(2015) Yujia Kong et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults

(2015) Masanari Shiramoto et al.   Human Vaccines & Immunotherapeutics

Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

(2015) Miwako Kobayashi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Against Community-Acquired Pneumonia in the General Population Aged >=60 Years: 3 Years of Follow-up in the CAPAMIS Study

(2014) O. Ochoa-Gondar et al.   CLINICAL INFECTIOUS DISEASES

Evaluating Clinical Effectiveness of Pneumococcal Vaccination in Preventing Stroke: The CAPAMIS Study, 3-Year Follow-up

(2014) Angel Vila-Corcoles et al.   Journal of Stroke & Cerebrovascular Diseases

Antibody and Plasmablast Response to 13-Valent Pneumococcal Conjugate Vaccine in Chronic Lymphocytic Leukemia Patients – Preliminary Report

(2014) Marcin Pasiarski et al.   PLoS One

The CAPITA study of protein-conjugate pneumococcal vaccine and its implications for use in adults in developed countries

(2014) Daniel M Musher et al.   Human Vaccines & Immunotherapeutics

Preventing non bacteremic pneumococcal pneumonia in older adults

(2014) David S Fedson   Human Vaccines & Immunotherapeutics

Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy

(2014) Kuan-Yeh Lee et al.   Human Vaccines & Immunotherapeutics

The ‘captain of the men of death’,Streptococcus pneumoniae, fights oxidative stress outside the ‘city wall’

(2013) Alexandra Gennaris et al.   EMBO Molecular Medicine

Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations

(2013) M. Hackel et al.   VACCINE

Evaluating the clinical effectiveness of pneumococcal vaccination in preventing myocardial infarction: The CAPAMIS study, three-year follow-up

(2013) O. Ochoa-Gondar et al.   VACCINE

Outpatient-Based Pneumococcal Vaccine Campaign and Survey of Perceptions about Pneumococcal Vaccination in Patients and Doctors

(2013) Joon Young Song et al.   YONSEI MEDICAL JOURNAL

Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons

(2013) Angela Domínguez et al.   Human Vaccines & Immunotherapeutics

Uptake of Pneumococcal Polysaccharide Vaccination Among Working-age Adults With Underlying Medical Conditions, United States, 2009

(2012) P.-J. Lu et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview

(2012) Angel Vila-Corcoles et al.   Expert Review of Vaccines

Biochemical, Genetic, and Serological Characterization of Two Capsule Subtypes amongStreptococcus pneumoniaeSerotype 20 Strains

(2012) Juan J. Calix et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pneumococcal vaccines WHO position paper – 2012 – Recommendations

(2012) WHO Publication   VACCINE

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales

(2012) Nick J. Andrews et al.   VACCINE

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe

(2011) David S Fedson et al.   Expert Review of Vaccines

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

(2011) Elizabeth Miller et al.   LANCET INFECTIOUS DISEASES

Pneumococcal Nasopharyngeal Carriage Among Infants Born to Human Immunodeficiency Virus-infected Mothers Immunized With Pneumococcal Polysaccharide Vaccine During Gestation

(2011) Volia de Carvalho Almeida et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections

(2011) Andreia N. Horácio et al.   VACCINE

Predictors of infection in chronic lymphocytic leukaemia (CLL)

(2010) H. GRIFFITHS et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Prevention of Acute Myocardial Infarction and Stroke among Elderly Persons by Dual Pneumococcal and Influenza Vaccination: A Prospective Cohort Study

(2010) Ivan F. N. Hung et al.   CLINICAL INFECTIOUS DISEASES

Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies

(2010) A. WONG et al.   EPIDEMIOLOGY AND INFECTION

A longitudinal study of class and subclass antibody response to pneumococcal vaccination in splenectomized individuals with special reference to patients with Hodgkin's disease

(2010) G. Grimfors et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review

(2010) RH Pedersen et al.   HIV MEDICINE

Pneumococcal Vaccination and Risk of Acute Myocardial Infarction and Stroke in Men

(2010) Hung Fu Tseng   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

(2010) Susan B. Manoff et al.   JOURNAL OF INFECTIOUS DISEASES

Risk of invasive pneumococcal infections among working age adults with asthma

(2010) P. Klemets et al.   THORAX

Pneumococcal vaccination and myocardial infarction

(2009) E. M. Rosa et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

(2009) Katherine L O'Brien et al.   LANCET

Multiple‐dose granulocyte‐macrophage–colony‐stimulating factor plus 23‐valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia

(2008) Amar Safdar et al.   CANCER

Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?

(2008) Angel Vila-Corcoles   LANCET INFECTIOUS DISEASES

The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with β-thalassemia

(2008) George V. Orthopoulos et al.   VACCINE